Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Jeong Hwan Park, Jung Ho Kim

Clin Mol Hepatol. 2019;25(1):12-20. Published online October 5, 2018

DOI: https://doi.org/10.3350/cmh.2018.0067

View: 25137 Download: 1,112 Web of Science: 38 Crossref: 42

Meyoung Cho, M.D., Chang Soo Choi, M.D., Geom Seog Seo, M.D., Tae Hyeon Kim, M.D., Suck Chei Choi, M.D., Ki Jung Yun, M.D. Haak Cheoul Kim, M.D.

Clin Mol Hepatol. 2007;13(2):234-238. Published online January 1, 1970

View: 2701 Download: 22

Ji Hoon Kim , Joong Won Park , Joon Il Choi , Hyun Beom Kim , Dong Wook Koh , Woo Jin Lee , Chang Min Kim

Clin Mol Hepatol. 2007;13(1):91-95. Published online January 1, 1970

View: 2882 Download: 19

Min An, M.D., Jeong A Shin, M.D., Sang-Min Lee, M.D., Tak Yoon, M.D. Weon Seo Park, M.D. Joon Il Choi, M.D., and Chang-Min Kim, M.D.

Clin Mol Hepatol. 2006;12(4):562-567. Published online January 1, 1970

View: 2801 Download: 31

1 |

Viewed By 5505	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5413	MAFLD: How is it different from NAFLD?
Viewed By 5222	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5101	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4732	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 90	MAFLD: How is it different from NAFLD?
Cited By 80	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search